Marcos orders FDA to further streamline drug approval process

Marcos orders FDA to further streamline drug approval process

By: - Reporter / @JMangaluzINQ
/ 01:50 PM February 13, 2024

PHOTO: Stock image of capsules and pills STORY: Marcos order FDA to further streamline drug approval process

President Ferdinand Marcos Jr. orders the Food and Drug Administration (FDA) to simplify its drug approval process further as he expressed his wish for medicines to become more accessible to Filipinos, following a sectoral meeting with FDA officials in Malacañang on Tuesday, February 13, 2024. (INQUIRER STOCK IMAGE)

MANILA, Philippines — President Ferdinand Marcos Jr. on Tuesday directed the Food and Drug Administration (FDA) to simplify its drug approval process further.

Following a sectoral meeting with FDA officials in Malacañang, the President said he wanted medical drugs to be more accessible to Filipinos.

Article continues after this advertisement

“The President has directed the Food and Drug Administration to further streamline the drug application process in the Philippines and to provide further drug accessibility for all the Filipinos, and in the future, the cheaper medicine for us, to be accessible also to the Filipino people,” FDA Director General Samuel Zacate said in a press briefing.

FEATURED STORIES

READ: Beware of uncertified cosmetic products – FDA

READ: India, PH in talks to set up ‘pharma zones’

Article continues after this advertisement

The FDA official said they are already working on several policy changes to help increase access to medicines.

Article continues after this advertisement

“We tackled in the sectoral meeting the possibility or the establishment of the pharma-zones,” said Zacate.

Article continues after this advertisement

The FDA said pharma-zones established in Philippine Economic Zone Authority-controlled areas will serve as places where the agency can immediately test and register medicines as they enter the country.

Zacate also said the FDA will lengthen the validity of current medicines from a five-year renewal period to 10 years.

Article continues after this advertisement

“We are doing the revision of fees for us to be capacitated so that our laboratory and testing abilities will be further and be at par with the other international regulations,” he said.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: drug approval, Food and Drug Administration, Medicines

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.